Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Covalent docking-based virtual screening and molecular dynamics simulations identify C02b as a potential KRAS(G12C) inhibitor
Download
manuscript_td04335.pdf
Date
2024-12-01
Author
Merve Bostancioglu, Safiye
Acar, Ahmet
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
95
views
130
downloads
Cite This
Decades of efforts to target the “undruggable” Kirsten rat sarcoma viral oncogene homolog (KRAS) oncoprotein yielded promising results in 2021 with the approval of Sotorasib, a KRAS(G12C) inhibitor for non-small cell lung cancer patients with the KRAS(G12C) variant. Before Sotorasib’s approval, developing KRAS(G12C) covalent inhibitors faced challenges, particularly their inability to preserve the KRAS protein in the GDP-bound state, which hindered clinical trial progression. Considering the importance of developing inhibitors targeting KRAS(G12C), we aimed to identify compounds analogous to Sotorasib, resulting in the discovery of a total of 174 Sotorasib scaffold-compounds. We then performed covalent docking-based virtual screening to examine the binding affinity of Sotorasib-like compounds to KRAS(G12C). Four compounds showed comparable binding energies according to Glide score to Sotorasib for targeting KRAS(G12C). Subsequently, molecular dynamics (MD) simulations were conducted for these four compounds, spanning 100 ns, 300 ns, and 500 ns durations, to identify the most stable complex with the lowest root-mean-square deviation (RMSD), similar to the KRAS(G12C)-Sotorasib reference complex. Additional dynamic cross-correlation matrix and PCA were performed as post-MD analyses to investigate the movements of two switches and the flexible regions of KRAS(G12C)-Sotorasib and -C02b complexes. As a result, among these four compounds, KRAS(G12C)-C02b was found as the optimal candidate. Further investigations beyond this study may provide more insight into C02b’s inhibitory effect on KRAS(G12C), offering a deeper understanding of its potential as a therapeutic agent.
URI
https://api-journal.accscience.com/uploads/file/20250317/4f5c8cf28ca0bdcdcfc3b7e00402354a.pdf
https://hdl.handle.net/11511/118174
Journal
Tumor Discovery
DOI
https://doi.org/10.36922/td.5163
Collections
Department of Biology, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
S. Merve Bostancioglu and A. Acar, “Covalent docking-based virtual screening and molecular dynamics simulations identify C02b as a potential KRAS(G12C) inhibitor,”
Tumor Discovery
, vol. 4, no. 1, pp. 1–10, 2024, Accessed: 00, 2025. [Online]. Available: https://api-journal.accscience.com/uploads/file/20250317/4f5c8cf28ca0bdcdcfc3b7e00402354a.pdf.